Mankind Pharma Ltd

Mankind Pharma Ltd

₹ 2,576 -0.65%
30 Jul - close price
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]
- #1 Rank in Prescriptions over the last 8 yrs.
- #2 Rank by volume & #4 Rank by value in IPM
- 4 Consumer healthcare brands ranked #1 in their categories.

  • Market Cap 1,06,384 Cr.
  • Current Price 2,576
  • High / Low 2,674 / 1,910
  • Stock P/E 47.0
  • Book Value 397
  • Dividend Yield 0.04 %
  • ROCE 13.7 %
  • ROE 13.8 %
  • Face Value 1.00

Pros

  • Company has reduced debt.

Cons

  • Tax rate seems low
  • Promoter holding has decreased over last 3 years: -3.87%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
2,092 2,260 2,209 2,007 2,413 2,544 2,414 2,119 2,570 2,609 2,633 2,582 2,964
1,594 1,662 1,636 1,482 1,837 1,781 1,668 1,778 1,885 1,916 1,854 1,663 2,035
Operating Profit 498 598 573 526 576 763 746 342 685 693 778 919 929
OPM % 24% 26% 26% 26% 24% 30% 31% 16% 27% 27% 30% 36% 31%
87 84 92 109 125 139 70 220 65 78 -27 104 34
Interest 2 4 4 4 7 3 200 162 149 147 138 125 95
Depreciation 69 77 90 87 91 90 91 115 105 99 108 109 111
Profit before tax 514 601 571 543 603 810 525 284 496 525 505 788 757
Tax % 20% 21% 15% 14% 16% 20% 22% 16% 16% 13% 11% 9% 26%
409 473 487 468 506 645 412 238 415 459 449 714 558
EPS in Rs 10.22 11.80 12.16 11.68 12.62 16.11 9.99 5.77 10.06 11.12 10.87 17.29 13.52
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
3,918 3,829 4,794 5,530 7,486 8,127 8,629 9,507 10,421 10,787
3,141 3,124 3,550 4,151 5,644 6,429 6,358 7,082 7,333 7,468
Operating Profit 778 705 1,244 1,379 1,842 1,698 2,272 2,425 3,088 3,319
OPM % 20% 18% 26% 25% 25% 21% 26% 26% 30% 31%
209 64 94 148 200 163 369 555 218 189
Interest 18 40 11 8 48 28 17 378 562 506
Depreciation 28 38 62 78 123 270 335 395 429 427
Profit before tax 941 691 1,265 1,440 1,871 1,563 2,289 2,208 2,315 2,574
Tax % 26% 26% 24% 25% 26% 20% 18% 19% 12%
694 514 958 1,084 1,389 1,248 1,876 1,786 2,038 2,180
EPS in Rs 17.33 12.83 23.92 27.07 34.68 31.16 46.84 43.29 49.36 52.80
Dividend Payout % 0% 0% 32% 0% 0% 0% 0% 0% 2%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 9%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: 15%
3 Years: 20%
TTM: 35%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 13%
1 Year: 0%
Return on Equity
10 Years: %
5 Years: 16%
3 Years: 15%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 40 40 40 40 40 40 40 41 41
Reserves 2,957 3,025 3,611 4,694 6,500 7,744 9,663 14,281 16,356
360 190 3 101 688 5 24 7,383 5,571
652 596 877 1,045 1,710 1,583 1,790 2,752 2,658
Total Liabilities 4,009 3,851 4,531 5,880 8,939 9,371 11,516 24,458 24,625
534 778 945 987 2,927 3,142 3,552 4,076 3,926
CWIP 322 211 148 166 387 495 209 207 420
Investments 1,402 1,698 1,784 2,397 2,526 3,102 4,215 16,683 16,523
1,751 1,164 1,655 2,330 3,100 2,632 3,540 3,491 3,756
Total Assets 4,009 3,851 4,531 5,880 8,939 9,371 11,516 24,458 24,625

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
540 537 960 1,022 821 1,799 1,736 2,350 2,752
-516 -306 -396 -1,127 -1,360 -1,041 -1,665 -12,178 -388
8 -240 -559 89 579 -710 -5 9,816 -2,477
Net Cash Flow 31 -9 5 -16 40 48 66 -11 -113
Free Cash Flow 309 371 795 830 -1,360 1,219 1,456 1,996 2,317
CFO/OP 102% 111% 99% 103% 70% 123% 95% 116% 104%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 23 13 32 24 23 22 33 35 41
Inventory Days 120 126 124 169 183 132 160 154 151
Days Payable 115 101 113 122 133 103 75 80 95
Cash Conversion Cycle 27 38 43 72 73 52 118 109 97
Working Capital Days 95 44 41 42 26 40 55 -81 -87
ROCE % 22% 36% 33% 30% 21% 24% 15% 14%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Chronic Share in Total Portfolio
%

Log in to view insights

Please log in to see hidden values.

Login
CVM (Covered Market) Share in Total IPM
%
Market Share by Value in IPM
%
Volume Share in IPM
%
Brand Families >INR 100 Cr
count
Field Force Size
count
Volume Growth
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
76.50% 76.50% 74.88% 74.87% 74.87% 72.71% 72.70% 72.67% 72.67% 72.66% 72.66% 72.63%
4.18% 6.74% 9.87% 11.58% 12.37% 13.34% 12.92% 13.07% 12.83% 11.34% 10.24% 9.45%
4.56% 9.78% 11.14% 9.94% 9.91% 11.05% 11.47% 11.50% 11.91% 13.26% 14.46% 15.39%
14.76% 6.97% 4.10% 3.61% 2.86% 2.89% 2.89% 2.75% 2.57% 2.75% 2.63% 2.53%
No. of Shareholders 1,34,7311,27,4491,35,1161,53,4501,63,8541,71,2811,80,5971,79,5491,70,3471,77,5391,77,6061,66,715

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls